Apex BiotechnologyTPE:1733 -0.17%81 PB Ratio is 1.60 as of Jul. 08, 2026, which is 4% below its 10-year median of 1.66. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,225 Biotechnology companies, Apex Biotechnology ranks better than 71.02% on this metric.
Apex Biotechnology Corp stock PB Ratio (=1.6) is close to 3-year low of 1.47.
The historical rank and industry rank for Apex Biotechnology's PB Ratio or its related term are showing as below:
TPE:1733'
s PB Ratio Range Over the Past 10 Years
Min: 1.12 Med: 1.66 Max: 2.74
Current: 1.6
During the past 13 years, Apex Biotechnology's highest PB Ratio was 2.74. The lowest was 1.12. And the median was 1.66.
TPE:1733's PB Ratio is ranked better than 71.02% of 1225
companies
in the Biotechnology industry
Industry Median: 2.92
vs TPE:1733: 1.60
During the past 12 months, Apex Biotechnology's average Book Value Per Share Growth Rate was 2.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 2.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 0.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Apex Biotechnology was 9.50% per year. The lowest was -5.40% per year. And the median was 1.15% per year.
Back to Basics: PB Ratio
Apex Biotechnology (TPE:1733) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Apex Biotechnology PB Ratio Related Terms
Apex Biotechnology PB Ratio Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Apex Biotechnology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's PB Ratio distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Apex Biotechnology (TPE:1733) has a PB Ratio of 1.60 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Apex Biotechnology and its competitors. This is near median its historical median of 1.66. Over the past decade, Apex Biotechnology's PB Ratio has ranged from 1.12 to 2.74. According to the industry distribution chart, Apex Biotechnology ranks #355 out of 1225 companies in the Biotechnology industry, placing it in the top 29%.
Is Apex Biotechnology's PB Ratio too high?
Apex Biotechnology's current PB Ratio of 1.60 is near median its 10-year median of 1.66. Over the past 10 years, this metric has ranged from a low of 1.12 to a high of 2.74. The Biotechnology industry median PB Ratio is 2.92. Apex Biotechnology's value of 1.60 is 45.2% below this industry median. Based on the distribution chart, Apex Biotechnology ranks #355 out of 1225 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #355 out of 1225 companies for PB Ratio. This puts Apex Biotechnology in the upper half of its industry. The industry median PB Ratio is 2.92. Apex Biotechnology's value of 1.60 is 45.2% below this benchmark. Historically, Apex Biotechnology's own PB Ratio has ranged from 1.12 to 2.74 over the past decade. While the company's 10-year median is 1.66 vs. the industry median of 2.92, Apex Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,225 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apex Biotechnology's current PB Ratio of 1.60 is 45.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Apex Biotechnology and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Biotechnology's current PB Ratio is 1.60, which is near median its own 10-year median of 1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$29.90 — trading 0.6% below its estimated fair value. The current PB Ratio is 1.60, which is near median its 10-year median of 1.66 and 45.2% below the Biotechnology industry median of 2.92. Apex Biotechnology's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current PB Ratio is 1.60 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued.
The current stock price of NT$29.90 is trading 0.6% below its estimated GF Value™ of NT$30.08.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
PB Ratio: 1.60 (near median its 10-year median of 1.66)
GF Value™: NT$30.08 vs. price of NT$29.90 (0.6% below fair value)
Industry Position: 45.2% below the Biotechnology median (#355 of 1225)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
81GF Score
Get the complete analysis for TPE:1733
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
